Provided by Tiger Trade Technology Pte. Ltd.

Vanguard Health Care ETF

311.90
+0.18000.06%
Post-market: 311.900.00000.00%19:30 EDT
Volume:151.52K
Turnover:47.21M
Market Cap:18.77B
PE:33.86
High:313.00
Open:312.74
Low:310.31
Close:311.72
52wk High:330.75
52wk Low:263.00
Shares:60.18M
Float Shares:60.18M
Volume Ratio:0.85
T/O Rate:0.25%
Dividend:4.61
Dividend Rate:1.48%
EPS(TTM):9.21
EPS(LYR):41.51
ROE:3.75%
ROA:0.89%
PB:0.95
PE(LYR):7.51

Loading ...

US Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 28

Johnson & Johnson (JNJ) Gets a Buy from Scotiabank

TIPRANKS
·
Sep 28

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday as Oil Prices Rise

MT Newswires Live
·
Sep 28

Taking Ozempic? a Routine Eye Exam Could Help You Understand Your Risk for Vision Loss

Dow Jones
·
Sep 28

FDA Approves AbbVie’s JUVMO for Adults with Parkinson’s Disease

Reuters
·
Sep 28

U.S. FDA Approves Abbvie's Juvmo™ (Tavapadon) for Parkinson's Disease

THOMSON REUTERS
·
Sep 28

Abbvie - Juvmo Expected to be Available in the U.S. in October 2026

THOMSON REUTERS
·
Sep 28

Eli Lilly price target raised to $1,500 from $1,400 at JPMorgan

TIPRANKS
·
Sep 28

Merck in License Pact Worth up to $2.13 Billion with SciBrunch Therapeutics

Dow Jones
·
Sep 28

Lilly Launches Initiative to Expand Diabetes, Obesity Drug Access

MT Newswires Live
·
Sep 28

Eli Lilly launches ‘Lilly Change the Course Commitment’

TIPRANKS
·
Sep 28

Merck enters global license agreement with SciBrunch Therapeutics for SPR2015

TIPRANKS
·
Sep 28

Merck Enters into Exclusive Global License Agreement with Scibrunch Therapeutics for Spr2015, an Investigational Oral Kras G12d (On) Inhibitor

Reuters
·
Sep 28

Eli Lilly - to Register Diabetes and Obesity Medicines in Lmics and Expand Access

THOMSON REUTERS
·
Sep 28

Eli Lilly - Aims to Treat Equal Number of Patients in Lmics and High-Income Countries by 2040

THOMSON REUTERS
·
Sep 28

Merck & Co - to Record $400 Mln Pre-Tax Charge, $0.13 Per Share, in Q3 2026

THOMSON REUTERS
·
Sep 28

Merck & Co - Deal Includes $400 Mln Upfront, Total Potential Value $2.13 Bln; Deal Closed

THOMSON REUTERS
·
Sep 28

Merck & Co Inc: Under Agreement, Scibrunch Granted Co Exclusive Rights to Develop, Manufacture & Commercialize Spr2015 Worldwide

THOMSON REUTERS
·
Sep 28

JPMorgan Adjusts Price Target on Eli Lilly to $1,500 From $1,400, Maintains Overweight Rating

MT Newswires Live
·
Sep 28

Merck's Keytruda Subcutaneous Formulation Approved for Launch in China

Stock News
·
Sep 28